TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38831365

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Training and education for clinics
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Implementation strategies
Number of subjects: 15
Study: 38831409

Group type: EXPERIMENTAL
Intervention: Cancer training course
Number of subjects: 408
Study: 38831415

Group type: EXPERIMENTAL
Intervention: Integrated MOUD and HIV treatment/prevention through a mobile unit
Number of subjects: 5

Group type: COMPARATOR
Intervention: Epidemiological data
Number of subjects: 5
Study: 38832001

Group type: EXPERIMENTAL
Intervention: EPs® 7630
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control
Number of subjects: 208
Study: 38832105

Group type: EXPERIMENTAL
Intervention: Subcutaneous daratumumab
Number of subjects: 21
Study: 38832435

Group type: EXPERIMENTAL
Intervention: Analgesia Nociception Index
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 40
Study: 38832504

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg thrice daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 65
Study: 38832791

Group type: EXPERIMENTAL
Intervention: Surgical decompression and/or stabilization
Number of subjects: 280
Study: 38832837

Group type: EXPERIMENTAL
Intervention: Delirium screening
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: PICU stay longer than 15 days
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusions
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Propofol infusions
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Continuous infusions of opioids
Number of subjects: 1064

Group type: COMPARATOR
Intervention: Continuous infusions of ketamine
Number of subjects: 1064
Study: 38832949

Group type: EXPERIMENTAL
Intervention: Oral THC (10 mg)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 38832972

Group type: EXPERIMENTAL
Intervention: Isatuximab plus VRd
Number of subjects: 446

Group type: COMPARATOR
Intervention: VRd
Number of subjects: 446
Study: 38832995

Group type: EXPERIMENTAL
Intervention: Intracoronary pressure measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous administration of adenosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracoronary administration of adenosine
Number of subjects: 0
Study: 38833007

Group type: EXPERIMENTAL
Intervention: Intermittent-scanned continuous glucose monitoring (isCGM) system in group A
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intermittent-scanned continuous glucose monitoring (isCGM) system in group B
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Intermittent-scanned continuous glucose monitoring (isCGM) system in both groups
Number of subjects: 400
Study: 38833140

Group type: EXPERIMENTAL
Intervention: Stapokibart (75-600 mg, subcutaneous)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 38833144

Group type: EXPERIMENTAL
Intervention: IVL3001 (12-36 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IVL3001 (12-36 mg) every 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IVL3001
Number of subjects: 40
Study: 38833250

Group type: EXPERIMENTAL
Intervention: Psychiatric service dog for PTSD (n = 81)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care (n = 75)
Number of subjects: 156
Study: 38833312

Group type: EXPERIMENTAL
Intervention: CAR+ extracellular vesicles (CAR+EVs)
Number of subjects: 100
Study: 38833311

Group type: EXPERIMENTAL
Intervention: Olaparib treatment
Number of subjects: 0
Study: 38833348

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 473

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 473
Study: 38833360

Group type: EXPERIMENTAL
Intervention: Predictive ITPLT model for post-LT tolerance
Number of subjects: 2228

Group type: EXPERIMENTAL
Intervention: Clinical factors associated with tolerance achievement
Number of subjects: 2228

Group type: EXPERIMENTAL
Intervention: Successful tapering of immunosuppressants (IS)
Number of subjects: 2228
Study: 38833442

Group type: EXPERIMENTAL
Intervention: Inhaled xenon during targeted temperature management (TTM) at 33°C for 24 hours
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (TTM at 33°C without xenon)
Number of subjects: 110
Study: 38833560

Group type: EXPERIMENTAL
Intervention: Epinephrine dosing intervals less than 3 minutes
Number of subjects: 382
Study: 38833575

Group type: EXPERIMENTAL
Intervention: Experimental technique (inserting the orogastric tube through a modified nipple of a bottle)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual technique (inserting the tube directly into the newborn's mouth without support)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Experimental technique
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual technique
Number of subjects: 71
Study: 38833590

Group type: EXPERIMENTAL
Intervention: naproxen 500 mg twice daily for 10 days
Number of subjects: 123

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 123
Study: 38833643

Group type: EXPERIMENTAL
Intervention: Everolimus + Endocrine Therapy (ET) (10 mg orally once daily for 1 year)
Number of subjects: 1939

Group type: COMPARATOR
Intervention: Placebo + Endocrine Therapy (ET)
Number of subjects: 1939

Group type: EXPERIMENTAL
Intervention: Everolimus + ET in postmenopausal patients (N = 1,221)
Number of subjects: 1939

Group type: EXPERIMENTAL
Intervention: Everolimus + ET in premenopausal patients (N = 571)
Number of subjects: 1939
Study: 38833658

Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg orally once daily plus pembrolizumab 400 mg intravenously once every 6 weeks
Number of subjects: 480

Group type: COMPARATOR
Intervention: Standard of care (SOC) - investigator's choice of regorafenib or trifluridine/tipiracil
Number of subjects: 480
Study: 38833971

Group type: EXPERIMENTAL
Intervention: Durvalumab (10 mg/kg intravenously every 2 weeks)
Number of subjects: 1154
Study: 38833975

Group type: EXPERIMENTAL
Intervention: Cawthorne-Cooksey exercises
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mechanical hippotherapy exercises
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (Cawthorne-Cooksey)
Number of subjects: 50
Study: 38833992

Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733
Study: 38834087

Group type: EXPERIMENTAL
Intervention: Mitazalimab 900 μg/kg with mFOLFIRINOX
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mitazalimab 450 μg/kg with mFOLFIRINOX
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mitazalimab with mFOLFIRINOX
Number of subjects: 70
Study: 38834220

Group type: EXPERIMENTAL
Intervention: Clascoterone cream 1% applied twice daily for 14 days
Number of subjects: 69
Study: 38834226

Group type: EXPERIMENTAL
Intervention: Topical clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle gel (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAB
Number of subjects: 0
Study: 38834319

Group type: EXPERIMENTAL
Intervention: Postnatal administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prenatal and postnatal administration of allogeneic expanded human first trimester fetal liver MSCs (BOOST cells)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Historical and untreated prospective controls
Number of subjects: 18
Study: 38834351

Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38834399

Group type: EXPERIMENTAL
Intervention: Selinexor maintenance therapy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Selinexor maintenance therapy (TP53wt/pMMR EC)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (TP53wt/pMMR EC)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Selinexor maintenance therapy (TP53wt/dMMR EC)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo (TP53wt/dMMR EC)
Number of subjects: 113
Study: 38834393

Group type: EXPERIMENTAL
Intervention: Phenogroup 2 (PG2) - younger smokers with ST-segment elevation myocardial infarction
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Phenogroup 3 (PG3) - elderly patients with heart failure with preserved ejection fraction and conduction disturbances
Number of subjects: 1499

Group type: EXPERIMENTAL
Intervention: Phenogroup 4 (PG4) - patients with acute heart failure with reduced ejection fraction
Number of subjects: 1499

Group type: COMPARATOR
Intervention: Phenogroup 1 (PG1) - typically patients with non-ST-segment elevation myocardial infarction
Number of subjects: 1499
Study: 38834432

Group type: EXPERIMENTAL
Intervention: SYN023 (0.3 mg/kg)
Number of subjects: 448

Group type: COMPARATOR
Intervention: HRIG (0.133 mL/kg)
Number of subjects: 448
Study: 38834540

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 61
Study: 38834634

Group type: EXPERIMENTAL
Intervention: Probiotic (multispecies-multistrain)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Prebiotic (oat bran)
Number of subjects: 14
Study: 38834744

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy (CRT) followed by nivolumab (240 mg) and surgery
Number of subjects: 44
Study: 38834776

Group type: EXPERIMENTAL
Intervention: Personalized bacteriophage therapy (BT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Personalized bacteriophage therapy (BT) with concomitant antibiotics
Number of subjects: 100
Study: 38834847

Group type: EXPERIMENTAL
Intervention: 5-Cog paradigm
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1201
Study: 38834996

Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 94

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 94
Study: 38835035

Group type: EXPERIMENTAL
Intervention: Comprehensive gender-transformative intervention of sexual education (ENFOCATE -Focus-on-)
Number of subjects: 609
Study: 38835046

Group type: EXPERIMENTAL
Intervention: 2-month physical rehabilitation intervention program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 60
Study: 38835058

Group type: EXPERIMENTAL
Intervention: Community dialogue approach (FH=FW)
Number of subjects: 70
Study: 38835061

Group type: EXPERIMENTAL
Intervention: Early extubation (< 6 hours)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Delayed extubation (6-12 hours)
Number of subjects: 178
Study: 38835083

Group type: EXPERIMENTAL
Intervention: Blood-flow restricted resistance training (BFR-T) during a combined pre- and postoperative period for a total of 6-10 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (exact details not specified).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blood-flow restricted resistance training (BFR-T) with protein supplementation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (exact details not specified) with protein supplementation.
Number of subjects: 0
Study: 38835091

Group type: EXPERIMENTAL
Intervention: True-AI arm (AI-assisted interpretation of head CTA)
Number of subjects: 6450

Group type: COMPARATOR
Intervention: Sham-AI arm (Sham AI-assisted interpretation of head CTA)
Number of subjects: 6450

Group type: EXPERIMENTAL
Intervention: True-AI arm
Number of subjects: 6450

Group type: EXPERIMENTAL
Intervention: True-AI arm and Sham-AI arm
Number of subjects: 6450
Study: 38835104

Group type: EXPERIMENTAL
Intervention: Married marital status
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Higher physical health-related quality of life (HRQoL)
Number of subjects: 629

Group type: EXPERIMENTAL
Intervention: Greater levels of social support
Number of subjects: 629
Study: 38835146

Group type: EXPERIMENTAL
Intervention: Digitally delivered treatment comprising exercise and patient education
Number of subjects: 682

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 682
Study: 38835235

Group type: EXPERIMENTAL
Intervention: Upadacitinib 45 mg (induction)
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg, 15 mg (maintenance)
Number of subjects: 1021
Study: 38835333

Group type: EXPERIMENTAL
Intervention: Impedance-controlled RF ablation of the PNN
Number of subjects: 36
Study: 38835400

Group type: EXPERIMENTAL
Intervention: Potassium binders for treating hyperkalemia
Number of subjects: 0
Study: 38835548

Group type: EXPERIMENTAL
Intervention: TAU + EMDR
Number of subjects: 79

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 79
Study: 38836335

Group type: EXPERIMENTAL
Intervention: @ctivehip tele-rehabilitation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study: 38836358

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haptoglobin treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental model of AS in mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38836419

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38836471

Group type: EXPERIMENTAL
Intervention: Cytokine measurement in sputum samples during exacerbation
Number of subjects: 99
Study: 38836606

Group type: EXPERIMENTAL
Intervention: Active VNS paired with rehabilitation
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham stimulation paired with rehabilitation (Controls)
Number of subjects: 106
Study: 38836759

Group type: EXPERIMENTAL
Intervention: TRC102 + Temozolomide (TMZ)
Number of subjects: 19
Study: 38836997

Group type: EXPERIMENTAL
Intervention: Trastuzumab-dkst
Number of subjects: 59
Study: 38837034

Group type: EXPERIMENTAL
Intervention: Resin-based composite (RBC) (Spectrum TPH3, Dentsply Sirona)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Resin-modified glass ionomer cement (RMGIC) (Riva Light Cure, SDI)
Number of subjects: 33

Group type: COMPARATOR
Intervention: RMGIC
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both RBC and RMGIC
Number of subjects: 33
Study: 38837133

Group type: EXPERIMENTAL
Intervention: Skill-oriented, material-based cognitive behavioral therapy (SEKT)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Supportive, patient-centered, emotion-focused therapy (FEST)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Bipolar disorder type 2 (BD 2)
Number of subjects: 305
Study: 38837144

Group type: EXPERIMENTAL
Intervention: Abrocitinib, 200 mg, by mouth once daily for 12 weeks
Number of subjects: 20
Study: 38837194

Group type: EXPERIMENTAL
Intervention: VR dual-task training program
Number of subjects: 188

Group type: COMPARATOR
Intervention: VR headset app showing nature videos (Control)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Attention and working memory (Central Nervous System Vital Signs computerized cognitive battery)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Quality of life (World Health Organization-5 Well-Being Index)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (EQ-5D-5L)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Anxiety (General Anxiety Disorder 7-item questionnaire)
Number of subjects: 188
Study: 38837208

Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 412

Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Intramedullary fixation
Number of subjects: 412
Study: 38837237

Group type: EXPERIMENTAL
Intervention: Doxepin cream
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Enalapril ointment
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Massage therapy
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Pulsed high-intensity laser
Number of subjects: 1166
Study: 38837240

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 8449
Study: 38837273

Group type: COMPARATOR
Intervention: G2 (left heart disease)
Number of subjects: 308

Group type: COMPARATOR
Intervention: G2-3 (combined G2/3 and G3/2)
Number of subjects: 308

Group type: COMPARATOR
Intervention: G2
Number of subjects: 308

Group type: COMPARATOR
Intervention: G2 and G2-3
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: G3
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 308
Study: 38837707

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) levels ≤500 ng/ml
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) levels ≤200 ng/ml
Number of subjects: 174
Study: 38837825

Group type: EXPERIMENTAL
Intervention: Bronchodilator therapy (specific medication not mentioned), administered twice daily for 12 weeks.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group receiving placebo treatment for 12 weeks.
Number of subjects: 200
Study: 38837864

Group type: EXPERIMENTAL
Intervention: Weight-tiered dosing of pantoprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mg/kg total body weight dosing of pantoprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg lean body weight dosing of pantoprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDA-recommended weight-tiered dosing of pantoprazole
Number of subjects: 0
Study: 38837894

Group type: EXPERIMENTAL
Intervention: PIK3CA mutation in exon 20
Number of subjects: 1691

Group type: EXPERIMENTAL
Intervention: PIK3CA mutation in exon 20 in hormone receptor-positive HER2-positive breast cancer
Number of subjects: 1691

Group type: EXPERIMENTAL
Intervention: PIK3CA mutation
Number of subjects: 1691

Group type: EXPERIMENTAL
Intervention: PIK3CA hotspot mutation p.H1047R
Number of subjects: 1691

Group type: EXPERIMENTAL
Intervention: Hotspot mutations in exon 9
Number of subjects: 1691
Study: 38838026

Group type: EXPERIMENTAL
Intervention: Fedratinib
Number of subjects: 0
Study: 38838170

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 6138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6138
Study: 38838232

Group type: EXPERIMENTAL
Intervention: 90Y-aTac-BEAM AHCT
Number of subjects: 20
Study: 38838287

Group type: EXPERIMENTAL
Intervention: BEMPEG plus Nivolumab (NIVO)
Number of subjects: 623

Group type: COMPARATOR
Intervention: Tyrosine kinase inhibitors (TKI; sunitinib or cabozantinib)
Number of subjects: 623
Study: 38838311

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab plus ipilimumab
Number of subjects: 115
Study: 38838332

Group type: EXPERIMENTAL
Intervention: Wearable ring device
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Test device placed on the index finger
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Test device placed on the fingertip
Number of subjects: 11
Study: 38838403

Group type: EXPERIMENTAL
Intervention: Geriatric nursing-led sustainable heat prevention program (3 months duration, includes education on hydration, rest, protective clothing, and recognition of heat-related illnesses)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 120
Study: 38838460

Group type: EXPERIMENTAL
Intervention: Access anti-HBc Total assay
Number of subjects: 5983
Study: 38838477

Group type: EXPERIMENTAL
Intervention: Phoenix App Only
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Phoenix App + Nicotine Replacement Therapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Factoid (Control)
Number of subjects: 152
Study: 38838500

Group type: EXPERIMENTAL
Intervention: Pemigatinib 13.5 mg once daily in 21-day cycles (2 weeks on, 1 week off) until disease progression or unacceptable toxicity.
Number of subjects: 147
Study: 38838501

Group type: EXPERIMENTAL
Intervention: Nivolumab ± ipilimumab combined with stereotactic radiation therapy
Number of subjects: 78

Group type: COMPARATOR
Intervention: First-line chemotherapy
Number of subjects: 78
Study: 38838608

Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA) with dexmedetomidine and lidocaine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Opioid-based anesthesia (OA) with remifentanil
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Opioid-free anesthesia (OFA)
Number of subjects: 120
Study: 38838985

Group type: EXPERIMENTAL
Intervention: Postpartum planning intervention
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 320
Study: 38839047

Group type: EXPERIMENTAL
Intervention: Intravenous remdesivir
Number of subjects: 53
Study: 38839101

Group type: EXPERIMENTAL
Intervention: Peer comparison antibiotic prescribing feedback (intervention group)
Number of subjects: 5046

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 5046

Group type: EXPERIMENTAL
Intervention: Intervention group (overall)
Number of subjects: 5046

Group type: EXPERIMENTAL
Intervention: Intervention group (unnecessary prescribing)
Number of subjects: 5046

Group type: EXPERIMENTAL
Intervention: Intervention group (prolonged duration prescriptions)
Number of subjects: 5046

Group type: EXPERIMENTAL
Intervention: Intervention group (broad spectrum prescribing)
Number of subjects: 5046

Group type: EXPERIMENTAL
Intervention: Case-mix adjusted reports
Number of subjects: 5046

Group type: EXPERIMENTAL
Intervention: Emphasis on harms messaging
Number of subjects: 5046
Study: 38839252

Group type: EXPERIMENTAL
Intervention: Metformin use
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Duration of metformin use
Number of subjects: 346
Study: 38839251

Group type: EXPERIMENTAL
Intervention: Modified CycleGAN (Digital ray)
Number of subjects: 959

Group type: COMPARATOR
Intervention: Original CycleGAN
Number of subjects: 959
Study: 38839269

Group type: EXPERIMENTAL
Intervention: Mailed outreach plus patient navigation
Number of subjects: 2872

Group type: COMPARATOR
Intervention: Usual care with visit-based screening
Number of subjects: 2872